Venture Funding Deals: Spin-Outs From Axovant, Inovio & Sosei

3-V Biosciences Inc., which is developing drugs for cancer and nonalcoholic steatohepatitis (NASH), raised $18m through its Series E round. New investor and partner Ascletis Pharma Inc. led and was joined by Qianhai Ark (Cayman) Investment, New Enterprise Associates, and Kleiner Perkins. Purchasers committed to fund an additional $7m through a later round. The funding was announced concurrent with 3-V granting Ascletis exclusive rights to develop, manufacture, and sell its fatty acid synthase inhibitor TVB2640 (ASC40) in Greater China for NASH. Series E proceeds will support upcoming Phase II trials in the US and China of TVB2640. 

Apic Bio Inc. closed a $40m Series A round led by Morningside Venture Investments (adds a board member), which was joined by other new investor ALS Investment Fund, along with returning backers the Alpha-1 Project (TAP) and A1ATD Investors